Based on the Cambridge Cognition Holdings Plc stock forecast from 0 analysts, the average analyst target price for Cambridge Cognition Holdings Plc is not available over the next 12 months. Cambridge Cognition Holdings Plc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cambridge Cognition Holdings Plc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Cambridge Cognition Holdings Plc’s stock price was GBX 52.00. Cambridge Cognition Holdings Plc’s stock price has changed by +0.00% over the past week, -7.14% over the past month and -46.67% over the last year.
No recent analyst target price found for Cambridge Cognition Holdings Plc
No recent average analyst rating found for Cambridge Cognition Holdings Plc
Company Overview Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for drug development by enabling pharmaceutical companies to take new therapeutics from preclinical consultancy to pivotal studies and approval, as well as supports sponsors to enhance recruitment, develop safe and effective treatments, and enhance research and development efficiency. It also provides CANTAB Connect Research, a proprietary platform that provides insights into behaviours, underlying brain circuits, and measurement of digital cognitive biomarkers; CANTAB Mobile, a touchscreen assessment of memory, mood, and functional status to detect the earliest signs of clinically relevant memory problems; CANTAB Insight to assess cognitive health; and CANTAB BrainHealth for assessing workplace wellbeing. In addition, the company offers electronic questionnaires and scales, a digital bespoke questionnaire; NeuroVocalix, a voice analysis platform to analyze voice to assess neurological change; cognition kit, a high frequency testing kit to detect changes over time and day-to-day cognition with short regular tests using patients' own devices. Cambridge Cognition Holdings Plc was incorporated in 2012 and is based in Cambridge, the United Kingdom. Read Less
Cambridge Cognition Holdings Plc, a neuroscience technology company, develops and markets near-patient cognitive testing techniques in the United States, United Kingdom, the European Union, and internationally. The company offers CANTAB digital cognitive assessment platform for d...Read More
Frequently Asked Questions About Cambridge Cognition Holdings Plc (COG:LSE) Stock
Stock Target Advisor's fundamental analysis for Cambridge Cognition Holdings Plc's stock is Slightly Bearish.
Unfortunately we do not have enough data on COG:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on COG:LSE's stock to indicate what its average analyst target is.
COG:LSE stock's Price/Earning ratio is 93.50.
Our analysis grades COG:LSE stock's Price / Earning ratio at D+. This means that COG:LSE stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Health Information Services sector in the LSE exchange.
Based on this COG:LSE may be fairly valued for its sector
The last closing price of COG:LSE's stock was GBX 52.00.
The most recent market capitalization for COG:LSE is GBX 0.02B.
Unfortunately we do not have enough analyst data on COG:LSE's stock to indicate whether its price will go up or not.
Following are ETFs with the highest allocation to Cambridge Cognition Holdings Plc's stock :
As per our most recent records Cambridge Cognition Holdings Plc has 80 Employees.
Cambridge Cognition Holdings Plc's registered address is Tunbridge Court, Cambridge, United Kingdom, CB25 9TU.
You can get more information about it from Cambridge Cognition Holdings Plc's website at https://www.cambridgecognition.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for COG:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
